Breaking News

BMS to Advance F-star Alpha HER2 Therapy

Gains exclusive option to acquire F-star Alpha and lead anti-cancer asset

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb and F-star Alpha Ltd. have entered an agreement that provides BMS the exclusive option to acquire F-star Alpha and gain worldwide rights to its lead asset FS102, a Human Epidermal growth factor Receptor 2 (HER2)-targeted therapy in Phase I development for breast and gastric cancer.   BMS will make payments totaling $50 million that consist of an option fee for the right to acquire F-star Alpha, certain rights and licenses, and a clinical milestone payment for the Phase I tri...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters